Pain Research Unit, Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, UK.
J Clin Invest. 2010 Nov;120(11):3753-9. doi: 10.1172/JCI43195. Epub 2010 Nov 1.
Despite intensive research into pain mechanisms and significant investment in research and development, the majority of analgesics available to prescribers and patients are based on mechanistic classes of compounds that have been known for many years. With considerable ingenuity and innovation, researchers continue to make the best of the mechanistic approaches available, with novel formulations, routes of administration, and combination products. Here we review some of the mechanisms and modalities of analgesics that have recently entered into clinical development, which, coupled with advances in the understanding of the pathophysiology of chronic pain, will hopefully bring the promise of new therapeutics that have the potential to provide improved pain relief for those many patients whose needs remain poorly met.
尽管对疼痛机制进行了深入研究，并在研究和开发方面投入了大量资金，但可用于处方和患者的大多数镇痛药都基于多年来已知的机制化合物类别。研究人员凭借极大的创造力和创新精神，继续充分利用现有的机制方法，开发出新型制剂、给药途径和联合产品。在这里，我们回顾了一些最近进入临床开发的镇痛药的机制和方式，再加上对慢性疼痛病理生理学理解的进步，有望带来新疗法的希望，这些新疗法有可能为那些需求仍未得到满足的许多患者提供更好的疼痛缓解。
